Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 15;14(7):1469. doi: 10.3390/pharmaceutics14071469

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Scatterplots of significantly enriched phosphorylated proteins against physiologically associated proteins significantly enriched in phosphorylation following (a) vehicle, (c) acidified pH, and (e) 60 mM KCl insult. Individual fold change plots of phosphorylation-site enrichment, separated by (b) vehicle-enriched, (d) acidified pH-enriched, and (f) 60 mM KCl-enriched phosphorylation; individual dots on these plots correspond to listed verified detected PTM sites. When separated by treatment group, unique patterns of phosphorylation of ZO-1 can be identified by individual treatment, indicating PTM-regulated protein trafficking converges on this protein. Italicized proteins in scatterplots lacking verifiable phosphorylation sites were not included in individual fold change plots. Individual phosphorylated residues are colored red and superscript indicates position of phosphorylated amino acid; residue sequences marked with an asterisk indicate isobaric phosphorylation sites and were graphed as individual iterations of phosphopeptide enrichment. (g) Venn diagram illustrating overlap of phosphorylation adduct sites on ZO-1 residues by treatment group.

Scatterplots of significantly enriched phosphorylated proteins against physiologically associated proteins significantly enriched in phosphorylation following (a) vehicle, (c) acidified pH, and (e) 60 mM KCl insult. Individual fold change plots of phosphorylation-site enrichment, separated by (b) vehicle-enriched, (d) acidified pH-enriched, and (f) 60 mM KCl-enriched phosphorylation; individual dots on these plots correspond to listed verified detected PTM sites. When separated by treatment group, unique patterns of phosphorylation of ZO-1 can be identified by individual treatment, indicating PTM-regulated protein trafficking converges on this protein. Italicized proteins in scatterplots lacking verifiable phosphorylation sites were not included in individual fold change plots. Individual phosphorylated residues are colored red and superscript indicates position of phosphorylated amino acid; residue sequences marked with an asterisk indicate isobaric phosphorylation sites and were graphed as individual iterations of phosphopeptide enrichment. (g) Venn diagram illustrating overlap of phosphorylation adduct sites on ZO-1 residues by treatment group.